Skip to main content

Table 2 Clinicopathological features of miR-663a expression in hepatocellular carcinoma patientsa

From: miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma

Clinicopathological features

No. of cases (N = 186)

miR-663a expression

P-value

High (n %)

Low (n %)

Age (year)

 ≥50

156

80(86.0%)

76(81.7%)

0.550

 <  50

30

13(14.0%)

17(18.3%)

Gender

 Male

160

78(83.9%)

82(88.2%)

0.527

 Female

26

15(16.1%)

11 (11.8%)

HBsAg status

 Positive (+)

132

63(67.7%)

69(74.2%)

0.419

 Negative (−)

54

30(32.3%)

24(25.8%)

Cirrhosis

 YES

131

64(68.8%)

67(72%)

0.748

 NO

55

29(31.2%)

26(28%)

AFP (ng/ml)

 ≥7

109

57(61.3%)

52(55.9%)

0.552

 <  7

77

36(38.7%)

41(44.1%)

PVTT

 YES

37

15(16.1%)

22(23.7%)

0.270

 NO

149

78(83.9%)

71(76.3%)

Tumor size(cm)

 ≥5

111

48(51.6%)

63(67.7)

0.036*

 <  5

75

45(48.4%)

30(32.3)

Tumor number

 Single

38

28(30.1%)

10(10.8%)

0.002*

 Multiple

148

65(69.9%)

83(89.2%)

Tumor differentiation

 Well-moderate

151

72(86.0%)

79(84.9%)

0.129

 Poor

35

21(14.0%)

14(15.1%)

TNM stage (Edition 7th)

 I

118

62(66.7%)

56(60.2%)

0.341

 II

36

17(18.3%)

19(20.4%)

 III

32

14(15.0%)

18(19.4%)

  1. aAFP α-fetoprotein, HBsAg Hepatitis B surface antigen, TNM Tumor-node-metastasis, PVTT Portal vein tumor thrombus
  2. *P < 0.05